activation in myocardium early after infarction Targeted imaging of hypoxia-induced integrin

[1]  A. Sinusas.  Imaging of angiogenesis , 2004, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[2]  A. Sinusas,et al.  Detection of Injury-Induced Vascular Remodeling by Targeting Activated &agr;vβ3 Integrin In Vivo , 2004 .

[3]  D. Dione,et al.  Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. , 2004, The Journal of clinical investigation.

[4]  S. Ylä-Herttuala,et al.  Evolving revascularization approaches for myocardial ischemia. , 2003, The American journal of cardiology.

[5]  J. Ware,et al.  Therapeutic angiogenesis in cardiovascular disease , 2003, Nature Reviews Drug Discovery.

[6]  S. Robinson,et al.  Design, synthesis, and evaluation of radiolabeled integrin αvβ3 receptor antagonists for tumor imaging and radiotherapy , 2003 .

[7]  C. Kumar.  Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. , 2003, Current drug targets.

[8]  M. Simons,et al.  Arteriogenesis: lessons learned from clinical trials. , 2003, Endothelium : journal of endothelial cell research.

[9]  Junichi Takagi,et al.  Global Conformational Rearrangements in Integrin Extracellular Domains in Outside-In and Inside-Out Signaling , 2002, Cell.

[10]  K. Shyu,et al.  Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. , 2002, Cardiovascular research.

[11]  David A. Cheresh,et al.  Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins , 2001, The Journal of cell biology.

[12]  S H Lee,et al.  Early expression of angiogenesis factors in acute myocardial ischemia and infarction. , 2000, The New England journal of medicine.

[13]  A. Rauth,et al.  BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  A. Sinusas.  The potential for myocardial imaging with hypoxia markers. , 1999, Seminars in nuclear medicine.

[15]  Weissleder,et al.  Approaches and agents for imaging the vascular system. , 1999, Advanced drug delivery reviews.

[16]  A. Nunn,et al.  Delineation of the border zone of ischemic rabbit myocardium by a technetium-labeled nitroimidazole. , 1997, Nuclear medicine and biology.

[17]  E. Engvall,et al.  Integrins and vascular extracellular matrix assembly. , 1997, The Journal of clinical investigation.

[18]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[19]  M. Detmar,et al.  Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. , 1996, The American journal of pathology.

[20]  R. Gibbons,et al.  Effects of scatter correction on the measurement of infarct size from SPECT cardiac phantom studies. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  T. Mulnix,et al.  Myocardial kinetics of a putative hypoxic tissue marker, 99mTc-labeled nitroimidazole (BMS-181321), after regional ischemia and reperfusion. , 1995, Circulation.

[22]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[23]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[24]  S. Kaul,et al.  An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. , 1992, The New England journal of medicine.

[25]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.